SRZN Surrozen Inc
1,190
$9.55
$0.60
(5.91%)
| Watchers | 1,190 |
| 52-Wk Low | $4.50 |
| 52-Wk High | $16.19 |
| Market Cap | $30.55M |
| Volume | 7,727.00 |
| 52-Wk High | $16.19 |
| 52-Wk Low | $4.50 |
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisGlobe Newswire • about 2 months ago
In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased pulmonary inflammation and fibrosis and improved lung function Surrozen Wnt mimetic SWAP...
Share to Feed
Surrozen announces up to $192.5M private placement of securities priced at-the-market under Nasdaq rules...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
- $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of warrants- Initial capital funds expansion of Phase 1b trial in severe alcohol-associated...
-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase 1a data demonstrated target engagement, a pharmacodynamic effect and effects on liver...
Surrozen, Inc. (NASDAQ:SRZN - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 3,400 shares, a growth of 25.9...
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...